DK1737961T3 - Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf - Google Patents
Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser derafInfo
- Publication number
- DK1737961T3 DK1737961T3 DK05728983.7T DK05728983T DK1737961T3 DK 1737961 T3 DK1737961 T3 DK 1737961T3 DK 05728983 T DK05728983 T DK 05728983T DK 1737961 T3 DK1737961 T3 DK 1737961T3
- Authority
- DK
- Denmark
- Prior art keywords
- cytotoxines
- bouganine
- proteins
- procedures
- modified
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55458004P | 2004-03-19 | 2004-03-19 | |
| US63057104P | 2004-11-26 | 2004-11-26 | |
| PCT/CA2005/000410 WO2005090579A1 (en) | 2004-03-19 | 2005-03-18 | Modified bouganin proteins, cytotoxins and methods and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1737961T3 true DK1737961T3 (da) | 2013-08-05 |
Family
ID=34993709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05728983.7T DK1737961T3 (da) | 2004-03-19 | 2005-03-18 | Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US7339031B2 (da) |
| EP (1) | EP1737961B1 (da) |
| JP (1) | JP5025460B2 (da) |
| KR (1) | KR101165867B1 (da) |
| AU (1) | AU2005224942B2 (da) |
| BR (1) | BRPI0508670B1 (da) |
| CA (1) | CA2560278C (da) |
| DK (1) | DK1737961T3 (da) |
| EA (1) | EA010803B1 (da) |
| ES (1) | ES2424643T3 (da) |
| HK (1) | HK1102306A1 (da) |
| IL (1) | IL177922A (da) |
| MX (1) | MXPA06010716A (da) |
| NO (1) | NO338293B1 (da) |
| NZ (1) | NZ550339A (da) |
| PL (1) | PL1737961T3 (da) |
| PT (1) | PT1737961E (da) |
| WO (1) | WO2005090579A1 (da) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2829283B1 (en) | 2003-04-30 | 2017-06-07 | Universität Zürich | Methods for treating cancer using an immunotoxin |
| EP2927322A1 (en) | 2004-06-10 | 2015-10-07 | Viventia Bio Inc. | Tumor specific antibody |
| KR101385886B1 (ko) | 2005-02-03 | 2014-04-24 | 안티토페 리미티드 | 인간 항체들과 단백질들 |
| NZ569450A (en) * | 2005-12-21 | 2012-01-12 | Viventia Biotech Inc | An isolated protein comprising a cancer-associated variant of Mammalian Scratch |
| AU2006329208B2 (en) | 2005-12-23 | 2012-03-08 | Viventia Bio Inc. | Methods for generating and screening fusion protein libraries and uses thereof |
| CA2668017A1 (en) * | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Improved conjugates |
| MX2009008230A (es) * | 2007-01-30 | 2010-03-08 | Epivax Inc | Epitopes de celulas t reguladoras, composiciones y usos para los mismos. |
| WO2008128330A1 (en) * | 2007-04-19 | 2008-10-30 | Viventia Biotech Inc. | Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins |
| US8252897B2 (en) * | 2007-06-21 | 2012-08-28 | Angelica Therapeutics, Inc. | Modified toxins |
| WO2009039630A1 (en) | 2007-09-27 | 2009-04-02 | Viventia Biotech Inc. | Optimized nucleic acid sequences for the expression of vb4-845 |
| EP2268297A4 (en) | 2008-02-29 | 2011-11-16 | Angelica Therapeutics Inc | MODIFIED TOXINS |
| US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
| WO2014127211A1 (en) * | 2013-02-15 | 2014-08-21 | Research Development Foundation | Deimmunized gelonin molecules and therapies |
| CA2902905A1 (en) | 2013-03-15 | 2014-09-25 | Claude Geoffrey Davis | Modified toxins |
| SG11201508419PA (en) * | 2013-04-12 | 2015-11-27 | Viventia Bio Inc | Compositions and methods for detection and treatment of hepatocellular carcinoma |
| KR102068519B1 (ko) | 2013-07-01 | 2020-01-21 | 삼성전자주식회사 | 저장 장치, 그것의 쓰기 방법 및 읽기 방법 |
| AU2014331494A1 (en) * | 2013-10-02 | 2016-04-07 | Viventia Bio Inc. | Anti-EpCAM antibodies and methods of use |
| US20160060358A1 (en) * | 2014-08-28 | 2016-03-03 | California Institute Of Technology | Induction of antigen-specific tolerance |
| US10583198B2 (en) | 2015-03-12 | 2020-03-10 | Viventia Bio Inc. | Dosing strategies for targeting EPCAM positive bladder cancer |
| US10576163B2 (en) | 2015-03-12 | 2020-03-03 | Viventia Bio Inc. | Methods of treatment for EpCAM positive bladder cancer |
| WO2016187571A2 (en) * | 2015-05-20 | 2016-11-24 | Viventia Bio Inc. | Her2 immunotoxins and methods of using the same |
| US20200390861A1 (en) | 2017-10-10 | 2020-12-17 | Medicenna Therapeutics, Inc. | Il-4-fusion formulations for treatment of central nervous system (cns) tumors |
| JP2022512533A (ja) * | 2018-08-10 | 2022-02-07 | サンフォード バーンハム プレビス メディカル ディスカバリー インスティテュート | 腫瘍関連マクロファージへの分子の結合およびその使用方法 |
| JP7124034B2 (ja) * | 2020-11-05 | 2022-08-23 | 株式会社天柳 | 嚥下困難者用食品組成物の製造方法 |
| JP7488928B1 (ja) | 2023-03-01 | 2024-05-22 | 積水フーラー株式会社 | ホットメルト接着剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6680295B1 (en) * | 1994-09-22 | 2004-01-20 | The Administrators Of The Tulane Educational Fund | Method and pharmaceutical composition for prevention and treatment of brain damage |
| US6121416A (en) * | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| AU8040898A (en) * | 1997-06-06 | 1998-12-21 | Tanox Pharma B.V. | Type-1 ribosome-inactivating protein |
| US6645494B1 (en) * | 1997-06-20 | 2003-11-11 | Tanox Pharma B.V. | Anti-CD40L immunotoxins for the treatment of diseases |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| ES2309167T3 (es) * | 2001-02-19 | 2008-12-16 | Merck Patent Gmbh | Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida. |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| BR0311720A (pt) | 2002-06-11 | 2005-03-01 | Merck Patent Gmbh | Método para mapear e eliminar epitopos de células t |
| US20060019885A1 (en) * | 2002-06-11 | 2006-01-26 | Matthew Baker | Modified bryodin 1 with reduced immunogenicity |
| CA2424255A1 (en) * | 2003-03-26 | 2004-09-26 | Claudio Di Paolo | Immunotoxins |
| US7696322B2 (en) * | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| EP2927322A1 (en) * | 2004-06-10 | 2015-10-07 | Viventia Bio Inc. | Tumor specific antibody |
| JP5143566B2 (ja) * | 2004-12-21 | 2013-02-13 | ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド | 癌特異的抗体および細胞表面タンパク質 |
| KR101385886B1 (ko) * | 2005-02-03 | 2014-04-24 | 안티토페 리미티드 | 인간 항체들과 단백질들 |
-
2005
- 2005-03-18 KR KR1020067021711A patent/KR101165867B1/ko active IP Right Grant
- 2005-03-18 JP JP2007503165A patent/JP5025460B2/ja active Active
- 2005-03-18 PT PT57289837T patent/PT1737961E/pt unknown
- 2005-03-18 DK DK05728983.7T patent/DK1737961T3/da active
- 2005-03-18 EP EP05728983.7A patent/EP1737961B1/en active Active
- 2005-03-18 AU AU2005224942A patent/AU2005224942B2/en active Active
- 2005-03-18 WO PCT/CA2005/000410 patent/WO2005090579A1/en active Application Filing
- 2005-03-18 MX MXPA06010716A patent/MXPA06010716A/es active IP Right Grant
- 2005-03-18 US US11/084,080 patent/US7339031B2/en active Active
- 2005-03-18 PL PL05728983T patent/PL1737961T3/pl unknown
- 2005-03-18 NZ NZ550339A patent/NZ550339A/en not_active IP Right Cessation
- 2005-03-18 ES ES05728983T patent/ES2424643T3/es active Active
- 2005-03-18 EA EA200601738A patent/EA010803B1/ru not_active IP Right Cessation
- 2005-03-18 CA CA2560278A patent/CA2560278C/en active Active
- 2005-03-18 BR BRPI0508670-1A patent/BRPI0508670B1/pt active IP Right Grant
-
2006
- 2006-09-06 IL IL177922A patent/IL177922A/en active IP Right Grant
- 2006-09-13 NO NO20064134A patent/NO338293B1/no unknown
-
2007
- 2007-09-27 HK HK07110463.0A patent/HK1102306A1/xx unknown
-
2008
- 2008-01-09 US US11/971,660 patent/US7750136B2/en active Active
-
2010
- 2010-05-21 US US12/784,820 patent/US8716234B2/en active Active
-
2014
- 2014-04-01 US US14/242,181 patent/US20150018526A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7339031B2 (en) | 2008-03-04 |
| NO20064134L (no) | 2006-11-08 |
| EP1737961A4 (en) | 2008-12-17 |
| MXPA06010716A (es) | 2007-02-21 |
| WO2005090579A1 (en) | 2005-09-29 |
| JP2008500811A (ja) | 2008-01-17 |
| US8716234B2 (en) | 2014-05-06 |
| EP1737961A1 (en) | 2007-01-03 |
| ES2424643T3 (es) | 2013-10-07 |
| JP5025460B2 (ja) | 2012-09-12 |
| AU2005224942A1 (en) | 2005-09-29 |
| IL177922A (en) | 2011-06-30 |
| NZ550339A (en) | 2009-11-27 |
| EA200601738A1 (ru) | 2007-04-27 |
| US20150018526A1 (en) | 2015-01-15 |
| PT1737961E (pt) | 2013-08-26 |
| CA2560278A1 (en) | 2005-09-29 |
| PL1737961T3 (pl) | 2013-12-31 |
| US20050238642A1 (en) | 2005-10-27 |
| US7750136B2 (en) | 2010-07-06 |
| US20080219994A1 (en) | 2008-09-11 |
| BRPI0508670A (pt) | 2007-08-14 |
| KR20070000494A (ko) | 2007-01-02 |
| EP1737961B1 (en) | 2013-05-08 |
| EA010803B1 (ru) | 2008-12-30 |
| BRPI0508670B1 (pt) | 2023-01-24 |
| IL177922A0 (en) | 2006-12-31 |
| US20100254964A1 (en) | 2010-10-07 |
| CA2560278C (en) | 2012-11-20 |
| AU2005224942B2 (en) | 2011-08-11 |
| HK1102306A1 (en) | 2007-11-16 |
| NO338293B1 (no) | 2016-08-08 |
| KR101165867B1 (ko) | 2012-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1737961T3 (da) | Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf | |
| NO20055018D0 (no) | Anti-amyolide antistoffer, sammensetninger, fremgangsmater og anvendelser | |
| DK1896073T3 (da) | Anti-il-antistoffer, sammensætninger, fremgangsmåder og anvendelser | |
| DK1868642T3 (da) | Katte-allergenfusionsproteiner og anvendelser deraf | |
| DK1904104T3 (da) | SP35-antistoffer og anvendelser heraf | |
| DK1680443T3 (da) | Stabiliserede alfa-helix-peptider og anvendelser heraf | |
| DK1844074T3 (da) | Humane antistoffer og proteiner | |
| DK3020729T3 (da) | Antistoffer mod human il-22 og anvendelser deraf | |
| DK1994055T3 (da) | Anti-5t4-antistoffer og anvendelser deraf | |
| DK2993187T3 (da) | Antistoffer rettet mod her-3 og anvendelser deraf | |
| NO20082454L (no) | Anti-alfa2 integrin antistoffer og deres anvendelser | |
| DK2418220T3 (da) | Interferon-alpha-antistoffer og anvendelser deraf | |
| DK2059535T3 (da) | Prlr-specifikt antistof og anvendelser deraf | |
| DK1894567T3 (da) | Ledsagende farmaceutiske midler og anvendelse deraf | |
| DK1866339T3 (da) | GTR-bindende molekyler og anvendelser heraf | |
| NO20054407D0 (no) | Cannabinoid reseptor ligander og deres anvendelser | |
| DK1780295T3 (da) | Svejseforbindelse og svejsemateriale deraf | |
| DK1971366T3 (da) | Humane anti-IL-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser | |
| NO20044073D0 (no) | Informasjonsbehandlingssystem og fremgangsmate | |
| DK1877090T3 (da) | Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf | |
| DK1673460T3 (da) | Rekombinante vacciner og anvendelse af disse | |
| DK1701968T3 (da) | Immunogene peptid-bærer-konjugater og fremgangsmåder til deres fremstilling | |
| DE60329983D1 (de) | Wachsestersynthase-dna-sequenz, protein und verwendungen davon | |
| NO20055731D0 (no) | Cannabinoide reseptorligander og deres anvendelse | |
| DK1846445T3 (da) | PYY-agonister og anvendelser deraf |